Abstract The US Food and Drug Administration approves tissue-agnostic therapies to target tumor biomarkers regardless of tumor type. In light of the growing number of… […]
GPR171, a Prognostic Marker of Improved Survival in Cervix Cancer – A Deep South Consortium in Oncology (DSCO) Project
